Results of a recent phase 2 clinical trial for Anlotinib showed that the novel tyrosine kinase inhibitor has some notable potential for treating locally advanced and metastatic medullary thyroid carcinoma. The news could turn out to have great significance, as patients only have a limited number of options available at the moment.
According to an article appearing in Thyroid publication, the team of researchers led by Yihebali Chi, MD, PhD from the Chinese Academy of Medical Sciences and Peking Union Medical College, China, observed aprogression-freee survival rate of 84.5% at 48 weeks, disease control rate of 93.1% and an objective response rate of 56.9%. The program was held between July 2013 and July 2014 at eight institutions in China, with 57 patients enrolled.
China does not support at the moment some of the other anticancer thyroid drugs, like Vandetanib and Cabozantinib (both approved for use by the FDA). Calcitonin, one possible alternative, recorded a response available for evaluation at 12 weeks in 87.9% of participants.
Overall, the treatment was well tolerated having manageable side effects. Most commonly, researchers noted hand-foot syndrome (79.31%), hypertriglyceridemia (46.55%), cholesterol elevation (43.1%) and fatigue (41.38%).
The conclusion was that “Anlotinib demonstrated a durable antitumor activity with a manageable adverse event profile in locally advanced or metastatic MTC”.
Thyroid carcinoma is a considerable problem in the Asian country, especially for the urban population, where the incidence rate is 2.5 times higher than in rural areas. Estimates indicate approximately 140.000 new cases each year with women being more at risk.
If following tests confirm its effectiveness, Anlotinib could prove to save countless lives.